EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


facebook twitter youtube

News archive

Recent news

   

The largest haematology meeting in the calendar year, the American Society of Hematology (ASH) Annual Meeting, was held virtually from 5 to 8 December 2020. Continue reading

   

A new study suggests the monoclonal antibody daratumumab has similar benefits when delivered via subcutaneous injection as it does when delivered intravenously to patients which myeloma persists or recurs after first-line treatments. Patients given subcutaneous daratumumab along with the immunomodulator pomalidomide and the anti-inflammatory steroid dexamethasone were 37% less likely to die or have their disease worsen compared to patients who received pomalidomide and dexamethasone alone in the phase III trial. Continue reading